MDR_Button Contact_Button News_Button  


CBA Pharma, Inc. has filed the New Drug Application (NDA) for the use of CBT-1® as an adjunct to chemotherapy in all cancer types with MDR. As a lead up to filing the NDA, CBA Pharma, Inc. conducted eight clinical trials to evaluate CBT-1® as a MDR modulator. Thirty-eight medical centers or cancer treatment centers participated in clinical trials. Patients were registered with the cancer types of Acute Myelogenous Leukemia, Breast, Non-Hodgkin’s Lymphoma, Hodgkin’s disease, Non-Small Cell Lung Cancer, Multiple Myeloma, Gallbladder, Pancreatic, Gastrointestinal Tract, Neuroendocrine, Mesothelioma, Small Cell Lung Cancer, Bladder, Head & Neck, Ovarian, Prostrate, and Sarcoma.


Column Header 1 Column Header 2 Column Header 3
CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1®, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy.
CBT-1®, taken orally as a pill, was developed to reverse multi-drug resistance in cancer cells and to become part of a Cancer Treatment Program that is administered before a cancer cell can become drug resistant.
(MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.


© CBA Pharma, Inc. 2014 All Rights Reserved Contact Us Privacy Statement Terms and Conditions